Study on Effects of Quantitative Neuromuscular Monitoring and Sugammadex Reversal in Elective Laparoscopic Gastric Bypass Surgery

What this Trial Is About

This research aims to evaluate how monitoring and reversal guidelines for neuromuscular blocking drugs affect outcomes after laparoscopic gastric bypass surgery. The study is a prospective, non-blinded, non-randomized before-and-after design conducted at a single site. It focuses on patients undergoing elective laparoscopic gastric bypass procedures and investigates the use of quantitative neuromuscular monitoring and the reversal agent sugammadex. Participants will experience quantitative electromyographic EMG monitoring during surgery to assess neuromuscular function. The study examines how adherence to muscle relaxant monitoring and reversal protocols influences postoperative results. The monitoring process uses a wearable device, and the study tracks the use of rocuronium and sugammadex doses within 24 hours post-surgery. During the study, participants will be assessed for oxygen desaturation within 24 hours after surgery as the primary outcome. Secondary outcomes include compliance with monitoring protocols, supplemental oxygen needs, lengths of stay in both postoperative units and the hospital over seven days, and the success rate of the wearable monitoring device. The total participation duration varies, with outcome measurements focused primarily within the first week after surgery.

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery